Cytokinetics (CYTK) CEO Robert I. Blum Exercises Options, Sells Shares

What Happened
Robert I. Blum, President & CEO and a director of Cytokinetics (CYTK), exercised stock options to acquire 7,500 shares at $10.60 per share (total cost $79,500) on July 27, 2026, and the same day sold 7,500 shares in an open-market transaction at $80.87 per share for proceeds of $606,525. The filing also shows a derivative disposition of 7,500 shares at $0.00; the Form 4 does not specify the reason for that zero‑consideration disposition.

Key Details

• Transaction date: 2026-07-27.
• Option exercise: 7,500 shares acquired at $10.60 each — $79,500 total (code M).
• Open-market sale: 7,500 shares sold at $80.87 each — $606,525 total (code S).
• Derivative disposition: 7,500 shares reported disposed at $0.00 (code M); no explanation provided in the filing.
• Shares owned after transaction: not specified in the information provided.
• Footnotes: F1 and F2 reference shares held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust.
• Timeliness: filing shows the report date as 2026-07-27; no late-filing flag is indicated in the provided data.

Context
Because the exercise and sale occurred the same day for the same number of shares, this appears to be an exercise followed by an immediate sale (often called a cashless or near-term sell following exercise). Such transactions commonly cover option exercise costs and taxes; they are routine insider liquidity events and are not, by themselves, definitive indicators of management’s view on longer-term company prospects.